Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48-week, Double-blind, Randomized, Parallel Phase I/II Study of Oral Rapamycin Versus Methotrexate in Systemic Sclerosis (Scleroderma)

NCT00241189 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT00241189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00241189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48-week, Double-blind, Randomized, Parallel Phase I/II Study of Oral Rapamycin Versus Methotrexate in Systemic Sclerosis (Scleroderma)
Lead sponsor
University of California, Los Angeles
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2002
Completion date
June 30, 2006
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis